AGM/EGMApr 29, 2026, 04:43 PM
CRMD 2026 AGM Proposals; 2025 Revenue $311.7M, Net Income $163M
AI Summary
CorMedix Inc. announced its 2026 Annual Meeting of Stockholders for June 23, 2026, where shareholders will vote on key proposals including director elections, auditor ratification, and several corporate governance amendments. The company reported a transformational 2025, achieving $311.7 million in total revenue and $163.0 million in net income, significantly up from a net loss in 2024, driven by DefenCath sales and the acquisition of Melinta Therapeutics. The proposed governance changes aim to streamline operations, align voting rights, and enhance officer protections.
Key Highlights
- 2026 Annual Meeting of Stockholders scheduled for June 23, 2026.
- Stockholders to vote on election of seven directors and auditor ratification.
- Proposals include ratification of Series E and C-3 Preferred Stock amendments.
- Proposals for technical amendments to the Charter and class voting rights.
- Proposals for exclusive forum designation and updating officer liability provisions.
- Total revenue for fiscal year 2025 reached $311.7 million.
- Net income for 2025 was $163.0 million, or $2.04 per diluted share.
- Acquisition of Melinta Therapeutics in August 2025 diversified product portfolio.